Patents by Inventor Cecilia Anna Wilhelmina Geuijen
Cecilia Anna Wilhelmina Geuijen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240118277Abstract: The present disclosure relates to a method for detecting and/or quantifying expression of at least a first cell surface moiety and of a second cell surface moiety in a patient sample, and to a method for detecting and/or quantifying clustering of at least a first cell surface moiety with a second cell surface moiety in a sample, wherein the sample is exposed to a molecule having binding specificity for the at least first and second cell surface moieties. The present disclosure further relates to a method for predicting the responsiveness of a subject to such binding molecule, a method for determining the effectiveness of such binding molecule, a method for confirming the mode of action of such binding molecule, a method for treating a subject, and a method for screening one or more test agents for the ability to induce clustering of a first cell surface moiety with a second cell surface moiety.Type: ApplicationFiled: September 28, 2021Publication date: April 11, 2024Inventor: Cecilia Anna Wilhelmina GEUIJEN
-
Publication number: 20240034794Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: ApplicationFiled: December 7, 2022Publication date: February 1, 2024Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20230406932Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.Type: ApplicationFiled: April 27, 2023Publication date: December 21, 2023Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Comelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20230357407Abstract: The disclosure provide means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variant thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: ApplicationFiled: July 26, 2023Publication date: November 9, 2023Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Patent number: 11780925Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.Type: GrantFiled: April 3, 2018Date of Patent: October 10, 2023Inventors: Mark Throsby, Cecilia Anna Wilhelmina Geuijen, David Andre Baptiste Maussang-Detaille, Ton Logtenberg
-
Patent number: 11773170Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.Type: GrantFiled: August 9, 2018Date of Patent: October 3, 2023Inventors: Cecilia Anna Wilhelmina Geuijen, Robertus Cornelis Roovers, Mark Throsby, Cornelis Adriaan De Kruif, Ton Logtenberg
-
Patent number: 11753470Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: GrantFiled: July 6, 2018Date of Patent: September 12, 2023Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Patent number: 11732043Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.Type: GrantFiled: July 6, 2018Date of Patent: August 22, 2023Assignee: MERUS N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Publication number: 20230242669Abstract: Abstract: The invention relates among others to antibodies comprising a first antigen- binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B- 3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb R-2/3 positive tumor.Type: ApplicationFiled: October 19, 2022Publication date: August 3, 2023Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Patent number: 11685786Abstract: The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.Type: GrantFiled: September 22, 2017Date of Patent: June 27, 2023Assignee: MERUS N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
-
Patent number: 11667714Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: GrantFiled: July 6, 2018Date of Patent: June 6, 2023Assignee: Merus N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Publication number: 20230159645Abstract: The present disclosure relates to a multispecific binding moiety comprising a PD-1 binding domain and a TGF-?RII binding domain, wherein the PD-1 binding domain blocks PD-1 mediated signaling and the TGF-?RII binding domain blocks TGF-?RII-mediated signaling. The present disclosure further relates to a pharmaceutical composition comprising such multispecific binding moiety, a method of treatment using such multispecific binding moiety, and a cell producing such multispecific binding moiety.Type: ApplicationFiled: November 18, 2022Publication date: May 25, 2023Applicants: MERUS N.V., Incyte CorporationInventors: Cecilia Anna Wilhelmina GEUIJEN, Patrick Mayes, Shaun M. Stewart, Liang-Chuan Wang
-
Publication number: 20220348683Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: ApplicationFiled: February 18, 2022Publication date: November 3, 2022Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Publication number: 20220127376Abstract: The invention provides a composition comprising two or more binding moieties wherein each of each of said binding moieties comprises a variable domain that binds to an extracellular part of EGFR; and wherein a first of said binding moieties comprises a variable domain that binds to an extracellular part of HER2 and a second of said binding moieties comprises a variable domain that binds to an extracellular part of HER3. The invention also relates to means and method for producing compositions and for the treatment of subjects with the compositions.Type: ApplicationFiled: February 13, 2020Publication date: April 28, 2022Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Tristan Louis Jean GALLENNE, Mark THROSBY, Cornelis Adriaan DE KRUIF
-
Patent number: 11279770Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: GrantFiled: February 27, 2015Date of Patent: March 22, 2022Assignee: Merus N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Cornelis Adriaan De Kruif, Mark Throsby, Ton Logtenberg, Alexander Berthold Hendrik Bakker
-
Publication number: 20210206875Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds ErbB-2 and a second antigen-binding site that binds ErbB-3. The antibodies can typically reduce a ligand-induced receptor function of ErbB-3 on a ErbB-2 and ErbB-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an ErbB-2, ErbB-3 or ErbB-2/3 positive tumor.Type: ApplicationFiled: April 3, 2018Publication date: July 8, 2021Inventors: Mark THROSBY, Cecilia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
-
Publication number: 20210054096Abstract: The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.Type: ApplicationFiled: May 17, 2018Publication date: February 25, 2021Inventors: David Andre Baptiste Maussang-Detaille, Cecilia Anna Wilhelmina Geuijen
-
Publication number: 20200325227Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: ApplicationFiled: July 6, 2018Publication date: October 15, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20200247892Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain, it may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.Type: ApplicationFiled: August 9, 2018Publication date: August 6, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan De Kruif, Ton Logtenberg
-
Publication number: 20200216539Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: ApplicationFiled: July 6, 2018Publication date: July 9, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG